ea0073aep256 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021
Iqbal Sajid
, Tikriti Alia Al
, Buckley Adam
BackgroundUse of Evolocumab as a monotherapy or in combination with other lipid lowering drugs reduces LDL-C by up to 60% in patients with or without familial hypercholesterolemia (FH), diabetes mellitus (DM), or coronary artery disease (CAD). Data regarding the efficacy of PCSK9 inhibitors in MENA populations is lacking.MethodRetrospective case review of all patients initiated on Evolocumab treatment at Impe...